ASH 2013: Highlights in Multiple Myeloma

Please Log In or Register to continue.

Release Date: December 19, 2013
Expiration Date: December 19, 2014

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

With an estimated 22,350 new cases of multiple myeloma and 10,710 deaths anticipated in the United States in 2013, multiple myeloma remains a challenging and currently incurable disease. Nevertheless, significant progress has been made in prolonging the survival of patients with multiple myeloma in the past decade through rapid advances in clinical research, and consequently it is transitioning to one more characteristic of a chronic disease. As a small population cancer, community oncology physicians and their multidisciplinary care team members, including oncology nurses and pharmacists, may have little real practice experience in managing this malignancy, so it becomes even more essential that community practitioners remain current with the most recent advances in diagnosis, monitoring, and treatment of multiple myeloma. However, busy community practitioners rarely have the time to attend large national meetings where clinical research findings are presented and interpreted as to their impact on practice. This activity is designed to provide highlights of the most promising multiple myeloma clinical studies presented at the American Society of Hematology (ASH) annual meeting held in New Orleans (December 5-9, 2013) with interpretation as to their potential impact on practice today and in the near future.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in the treatment of patients with multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize advances in HDT-ASCT: conditioning and consolidation regimens
  • List advances in maintenance or continuous therapy and approaches to frail and poor performance patients
  • Describe advances in smoldering myeloma, risk-stratification approaches, strategies for newly diagnosed MM patients
  • Define current trials and new agents in clinical investigation in newly diagnosed symptomatic myeloma and the relapsed/refractory setting

Agenda

ASH 2013: Highlights in Multiple Myeloma – Philip McCarthy, MD (Moderator)

Overview of Advances in Multiple Myeloma: ASH 2013 – Kenneth Anderson, MD

Advances in Newly Diagnosed Asymptomatic and Symptomatic Myeloma Treatment and Management – Thierry Facon, MD

Reducing Toxicity to Treatment and Improving Responses in Both Newly Diagnosed Good Performance As Well As Frail or Poor Performance Myeloma Patients – Antonio Palumbo, MD

Advances Addressing the Role of Transplant and Non-Transplant Approaches to Myeloma Patient Care – Koen van Besien, MD, PhD

Instructions for Participation and Credit
This activity is eligible for credit through December 19, 2014. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biographies

Philip McCarthy, MD
Professor of Oncology
Director, Blood and Marrow Transplant Program
Roswell Park Cancer Institute
Buffalo, New York

Dr. Philip McCarthy received his medical degree from Tufts University School of Medicine, Boston, Massachusetts. He completed an internship and residency at Yale-New Haven Hospital, as well as two fellowships at Brigham and Women's Hospital. Dr. McCarthy is professor of oncology and director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute, Buffalo. He is also associate professor of medicine at the State University of New York at Buffalo.

Dr. McCarthy is a diplomate, American Board of Internal Medicine, with subspecialty certification in medical oncology and hematology, and holds membership in the American Society of Hematology (ASH), American Society for Blood and Marrow Transplantation (ASBMT), American Society of Clinical Oncology (ASCO), American Association of Blood Banking, and American Association for Cancer Research (AACR). He is on the editorial board of Biology of Blood and Marrow Transplantation, Bone Marrow Research, and Bone Marrow Transplantation, as well as an ad hoc reviewer for Blood, Bone Marrow Transplantation, Cancer, Journal of Clinical Oncology, Haematologica, Leukemia and Lymphoma, Oncology, and JNCCN. Dr. McCarthy has published more than 150 peer-reviewed manuscripts and abstracts, and his major research interest areas include blood and marrow transplantation, chemotherapy toxicity, cancer immunotherapy, and multiple myeloma. He has been voted Best Doctors in America 2005-2011.

Kenneth C. Anderson, MD
Kraft Family Professor of Medicine
Harvard Medical School
Chief, Division of Hematologic Neoplasia
Director, Jerome Lipper Multiple Myeloma Center
Director, LeBow Institute for Myeloma Therapeutics
Dana-Farber Cancer Institute
Boston, Massachusetts

Dr. Kenneth Anderson graduated from Johns Hopkins Medical School, trained in internal medicine at Johns Hopkins Hospital, and completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. He is the Kraft Family Professor of Medicine at Harvard Medical School; and serves as chief of the Division of Hematologic Neoplasia, director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, and vice chair of the Joint Program in Transfusion Medicine at Dana-Farber Cancer Institute.

Dr. Anderson serves as chair of the NCCN Multiple Myeloma Clinical Practice Guidelines Committee; as a Cancer and Leukemia Group B Principal Investigator; on the Board of Scientific Advisors of the International Myeloma Foundation; and is on the Board of Directors and Chair of both the Scientific Advisory Board of the Multiple Myeloma Research Foundation and the Steering Committee of the Multiple Myeloma Research Consortium. Dr. Anderson has published more than 350 original articles, 250 chapters, has edited multiple textbooks on both multiple myeloma and on transfusion medicine, and was named editor in chief of Clinical Cancer Research. In addition, he is a Doris Duke Distinguished Clinical Research Scientist and has received numerous other awards.

Over the last two decades, Dr. Anderson has focused his translational research studies on B-cell malignancies, especially multiple myeloma. His team led both preclinical and clinical trials of the novel proteasome inhibitor bortezomib, as well as lenalidomide. His research offers great promise to improve patient outcome in hematologic malignancies and solid tumors.

Thierry Facon, MD
Professor of Hematology
University of Lille, France
Lille, France

Dr. Thierry Facon received his medical degree from the University of Lille, France where he is currently professor of hematology. He is past-president of the Intergroupe Francophone du Myélome of which he is still an active member, and is currently vice president of the French Society of Hematology. Dr. Facon has authored/co-authored more than 180 papers in various prestigious international journals including The Lancet and The New England Journal of Medicine.

Antonio Palumbo, MD
Chief, Myeloma Unit
Department of Oncology
University of Torino
Torino, Italy

Dr. Antonio Palumbo received his medical degree from the University of Torino, Italy, where he served his residency in internal medicine and held a fellowship in hematology/oncology. Before his current position as chief of the Myeloma Unit of the Department of Oncology, Section of Hematology at the University of Torino, Dr. Palumbo was a research associate at the Wistar Institute, University of Pennsylvania.

In addition to membership in numerous professional organizations, including the Italian Society of Hematology, Italian Society of Experimental Hematology, European Society of Hematology, American Society of Hematology, and the American Society of Clinical Oncology, Dr. Palumbo is on the Board of Directors of the International Myeloma Society. He has authored more than 150 publications in peer-reviewed journals as well numerous abstracts and several textbook chapters. Dr. Palumbo specializes in malignant hematology and medical oncology and has clinical and research interest in plasma cell dyscrasia, his current research focuses on the pathogenesis and treatment of multiple myeloma.

Koen van Besien, MD, PhD
Assistant Professor of Medicine
Director, Transplant Program
Division of Hematology and Medical Oncology
Weill-Cornell Medical College
New York, New York

Dr. Koen van Besien is a graduate of the College ND de la Paix in Namur, Belgium, and from the University of Leuven, Belgium, where he also did his clinical training in medicine. He holds a PhD from the University of Maastricht in the Netherlands and completed a hematology/oncology fellowship at Indiana University and in Bruges, Belgium. Dr. van Besien is director of the transplant program, Division of Hematology and Medical Oncology at Weill-Cornell. He is currently an assistant professor of medicine (provisional title) at Weill-Cornell Medical College and attending physician at the New York-Presbyterian Hospital.

Dr. van Besien has over 180 publications in peer-reviewed journals. He is a member of the editorial review boards of the journals Bone Marrow Transplantation and Biology of Blood and Marrow Transplantation. He is also editor-in-chief of the journal Leukemia and Lymphoma. He has established a national and international reputation with several research and clinical interests. Dr. van Besien has devoted considerable efforts at developing novel treatment strategies for patients with recurrent lymphoma, including the introduction of novel drugs and treatment in salvage therapy and in transplant conditioning regimens. He also has developed novel methods of transplantation for those patients who lack matching donors. Most recently, his group has described a novel concept of haplo-cord transplantation with extremely encouraging results.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-13-381-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 13-381-342

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made

Faculty Disclosures

Dr. Philip McCarthy has received honoraria related to speakers’ bureau activities from Celgene Corporation, Janssen Pharmaceuticals, Inc., and Onyx.

Dr. Kenneth Anderson has received honoraria related to formal advisory activities from Celgene Corporation, Gilead, Onyx, and sanofi-aventis U.S. LLC. He is the scientific founder of Acetylon Pharmaceuticals, Inc. and OncoPep.

Dr. Thierry Facon has received honoraria related to formal advisory activities from Bristol-Myers Squibb, Celgene Corporation, Janssen Pharmaceuticals, Inc., Millennium: The Takeda Oncology Company, Novartis AG, and Onyx, as well as speakers’ bureau activities from Celgene and Janssen.

Dr. Antonio Palumbo has received honoraria related to speakers’ bureau activities from Bristol-Myers Squibb, Celgene Corporation, Janssen Pharmaceuticals, Inc., Millennium: The Takeda Oncology Company, and Onyx.

Dr. Koen van Besien has disclosed no relevant financial relationships.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Drs. McCarthy, Anderson, Facon, and Palumbo have indicated that they do intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. van Besien has indicated that he does not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Anderson and Dr. van Besien have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Drs. McCarthy, Facon, and Palumbo have indicated that they do intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at info@managingmyeloma.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Millennium: The Takeda Oncology Company, Celgene Corporation, and Onyx Pharmaceuticals, Inc.

©2013 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.